Phase II Study of MK-2206 in Patients With Relapsed Lymphoma
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2016
At a glance
- Drugs MK 2206 (Primary)
- Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.